Analyst Activity – HC Wainwright Reiterates Buy on Antares Pharma (NASDAQ:ATRS)

0

Analyst Ratings For Antares Pharma (NASDAQ:ATRS)

Today, HC Wainwright reiterated its Buy rating on Antares Pharma (NASDAQ:ATRS).

Some recent analyst ratings include

  • 2/15/2018-HC Wainwright Reiterated Rating of Buy.
  • 6/23/2017-Chardan Capital initiated coverage with a Buy rating.
  • 4/20/2017-Raymond James Financial initiated coverage with a Strong-Buy rating.
  • 5/10/2016-Jefferies Group Reiterated Rating of Buy.

Recent Insider Trading Activity For Antares Pharma (NASDAQ:ATRS)
Antares Pharma (NASDAQ:ATRS) has insider ownership of 11.60% and institutional ownership of 34.67%.

  • On 10/9/2017 Leonard S Jacob, Director, sold 230,000 with an average share price of $4.05 per share and the total transaction amounting to $931,500.00.
  • On 10/3/2017 Thomas J Garrity, Director, sold 30,000 with an average share price of $3.50 per share and the total transaction amounting to $105,000.00.
  • On 6/9/2017 Fred M Powell, Insider, bought 130,000 with an average share price of $2.79 per share and the total transaction amounting to $362,700.00.
  • On 4/5/2017 Robert F Apple, CEO, sold 40,000 with an average share price of $3.00 per share and the total transaction amounting to $120,000.00.
  • On 4/4/2017 Leonard S Jacob, Director, sold 41,762 with an average share price of $2.89 per share and the total transaction amounting to $120,692.18.
  • On 4/4/2017 Robert F Apple, CEO, sold 37,000 with an average share price of $3.00 per share and the total transaction amounting to $111,000.00.
  • On 4/3/2017 Leonard S Jacob, Director, sold 20,000 with an average share price of $2.88 per share and the total transaction amounting to $57,600.00.

Recent Trading Activity for Antares Pharma (NASDAQ:ATRS)
Shares of Antares Pharma closed the previous trading session at 2.15 up +0.17 8.59% with 2421578 shares trading hands.

An ad to help with our costs